Pure Global

Nasal Irrigation Solution - Vietnam Registration 240000067/PCBA-LA

Access comprehensive regulatory information for Nasal Irrigation Solution in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại A medical device is registered under number 240000067/PCBA-LA and manufactured by YPharma Pharmaceutical Research and Manufacturing Corporation. The authorized representative in Vietnam is CÔNG TY CỔ PHẦN NGHIÊN CỨU VÀ SẢN XUẤT DƯỢC PHẨM YPHARMA.

This page provides complete technical specifications, regulatory compliance details, 5 companies making similar products including CÔNG TY CỔ PHẦN LIÊN DOANH CÔNG NGHỆ DƯỢC PHẨM VIỆT Ý, SHABIGROUP CORPORATION, and 5 recent registrations in the same category. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
5 Competitors
5 Recent Registrations
240000067/PCBA-LA
Registration Details
Vietnam MOH Registration: 240000067/PCBA-LA
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Nasal Irrigation Solution
VN: DUNG DỊCH XỊT MŨI
ANTIBABY VIFA
Risk Class TTBYT Loại A

Registration Details

240000067/PCBA-LA

000.00.17.H39-240620-0002

ANTIBABY VIFA

Company Information

CÔNG TY CỔ PHẦN NGHIÊN CỨU VÀ SẢN XUẤT DƯỢC PHẨM YPHARMA

Technical Details

-Nasal hygiene helps to deeply clean, supporting the prevention and reduction of the risk of nasal infections. It maintains the natural moisture of the nose, helping to protect and heal the nasal mucosa. -Supports the fight against bacteria and inflammation, preventing the invasion of viruses and bacteria, and reducing the risk of various types of rhinitis, including allergic rhinitis and rhinosinusitis. -Supports the relief of symptoms associated with nasal congestion, runny nose, itching, and postnasal drip, as well as upper respiratory tract infections and coughing. -Supports the reduction of the impact of allergens on the nasal mucosa.

Dates and Status

Jul 03, 2024